Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Malberti

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Journal of Nephrology|May 9, 2014
Management of mineral metabolism in hemodialysis patients: discrepancy between interventions and perceived causes of failurePasquale Esposito, Teresa Rampino, Marilena Gregorini, et al.
Journal of Nephrology|February 11, 2012
Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometryPaola Pecchini, Fabio Malberti, Maren Mieth, et al.
Journal of Nephrology|March 5, 2025
Treatment of secondary hyperparathyroidism in hemodialysis patients: a comparison between two Italian centers to evaluate real-world guideline implementationFabio Malberti, Stefano Possenti, Paola Pecchini, et al.
Clinical Kidney Journal|May 30, 2013
Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reductionEmanuel Zitt, Denis Fouque, Stefan H Jacobson, et al.
Journal of Clinical Medicine|July 24, 2019
Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life"Domenico Russo, Rocco Tripepi, Fabio Malberti, et al.
BMC Nephrology|April 18, 2015
Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational studyPiergiorgio Messa, Mario Cozzolino, Diego Brancaccio, et al.
Journal of Clinical Medicine|April 30, 2020
Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life". <i>J. Clin. Med.</i> 2019, <i>8</i>, 1066Domenico Russo, Rocco Tripepi, Fabio Malberti, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 24, 2010
Modeling survival of arteriovenous accesses for hemodialysis: semiparametric versus parametric methodsPietro Ravani, Patrick Parfrey, Jennifer MacRae, et al.
Journal of Nephrology|December 20, 2019
New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of NephrologyAntonio Bellasi, Mario Cozzolino, Fabio Malberti, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|May 23, 2018
[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy]Antonio Bellasi, Mario Cozzolino, Fabio Malberti, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of Nephrology|May 9, 2014
Management of mineral metabolism in hemodialysis patients: discrepancy between interventions and perceived causes of failurePasquale Esposito, Teresa Rampino, Marilena Gregorini, et al.
Journal of Nephrology|February 11, 2012
Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometryPaola Pecchini, Fabio Malberti, Maren Mieth, et al.
Journal of Nephrology|March 5, 2025
Treatment of secondary hyperparathyroidism in hemodialysis patients: a comparison between two Italian centers to evaluate real-world guideline implementationFabio Malberti, Stefano Possenti, Paola Pecchini, et al.
Clinical Kidney Journal|May 30, 2013
Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reductionEmanuel Zitt, Denis Fouque, Stefan H Jacobson, et al.
Journal of Clinical Medicine|July 24, 2019
Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life"Domenico Russo, Rocco Tripepi, Fabio Malberti, et al.
BMC Nephrology|April 18, 2015
Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational studyPiergiorgio Messa, Mario Cozzolino, Diego Brancaccio, et al.
Journal of Clinical Medicine|April 30, 2020
Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life". <i>J. Clin. Med.</i> 2019, <i>8</i>, 1066Domenico Russo, Rocco Tripepi, Fabio Malberti, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 24, 2010
Modeling survival of arteriovenous accesses for hemodialysis: semiparametric versus parametric methodsPietro Ravani, Patrick Parfrey, Jennifer MacRae, et al.
Journal of Nephrology|December 20, 2019
New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of NephrologyAntonio Bellasi, Mario Cozzolino, Fabio Malberti, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|May 23, 2018
[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy]Antonio Bellasi, Mario Cozzolino, Fabio Malberti, et al.
Pageof 6